NCT06867497View on ClinicalTrials.gov

A Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety Between Administration of BR2021 and BR2021-1

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 24, 2025

Primary Completion Date

October 28, 2025

Study Completion Date

October 28, 2025

Conditions
Metastatic Adenocarcinoma of the Pancreas
Interventions
DRUG

BR2021

intravenous administration for 30 minutes

DRUG

BR2021-1

intravenous administration for 30 minutes

Trial Locations (2)

Unknown

RECRUITING

Asan Medical Center, Seoul

RECRUITING

The Catholic University of Korea Seoul St. Mary's Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY